Simiso Sokhela

机构：University of the Witwatersrand · ORCID：0000-0002-2707-1533

发表论文 56 篇 · 总被引 1793 次 · h-index 17

代表论文

• Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial (2024 · The Lancet Infectious Diseases · 被引 101)
• Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens (2024 · Open Forum Infectious Diseases · 被引 40)
• The long wait for long-acting HIV prevention and treatment formulations (2024 · The Lancet HIV · 被引 27)
• Risks of metabolic syndrome in the ADVANCE and NAMSAL trials (2023 · Frontiers in Reproductive Health · 被引 17)
• Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial (2025 · Clinical Infectious Diseases · 被引 14)
• Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population (2023 · CPT Pharmacometrics & Systems Pharmacology · 被引 13)